RESUMO
PURPOSE: There are few studies published referring to bariatric surgery in patients older than 70 years. The aim of this study is to evaluate whether there are benefits to performing sleeve gastrectomy (SG) in patients over 70 years of age and to compare the results with a younger control group. MATERIALS AND METHODS: Data were retrospectively collected from a Private Clinic's electronic medical records of patients undergoing SG between June 2017 and September 2020. Inclusion criteria were patients older than 70 years [septuagenarian group (SpG)] who met all institutional protocols. Patients in the control group (CG) were selected with a 1:1 ratio and under 60 years of age, according to body mass index and comorbidities. The primary endpoint of the study was to evaluate the morbidity and mortality during the 30-day postoperative period and percentage of total weight loss (%TWL), and improvement of comorbidities after 1 year of follow-up. RESULTS: Fifty patients were included in the study. Both groups were similar regarding gender, weight, BMI, and presence of DM. The 30-day morbidity and mortality were similar between the groups. The patients in the SpG had 26.9% of %TWL and the CG, 28% (p = 0.32). The remission rate of DM (50% vs. 85% p = 0.01) and SAH (30% vs. 64% p = 0.04) was lower for septuagenarian patients. CONCLUSION: The sleeve gastrectomy surgery performed in patients over 70 years of age is safe. The early results suggest similar benefits regarding weight loss and improvement of comorbidities to those having SG before age 60.
Assuntos
Derivação Gástrica , Laparoscopia , Obesidade Mórbida , Idoso , Idoso de 80 Anos ou mais , Estudos de Casos e Controles , Gastrectomia/métodos , Derivação Gástrica/métodos , Humanos , Laparoscopia/métodos , Pessoa de Meia-Idade , Obesidade Mórbida/cirurgia , Estudos Retrospectivos , Resultado do Tratamento , Redução de PesoRESUMO
Resumen Prevenir la muerte súbita y aumentar la supervivencia y la calidad de vida en los pacientes con falla cardiaca son las principales indicaciones para el uso de los desfibriladores implantables y la terapia de resincronización cardiaca respectivamente. Hay certeza de la eficacia clínica de estos dispositivos para la población general; sin embargo, no es tan clara para los pacientes mayores de 70 años dado que esta población no está lo suficientemente representada en los diseños de los estudios clínicos. La evidencia disponible hasta el momento precisa que en este grupo etario existe beneficio de la terapia de resincronización cardiaca, pero es cuestionable el uso de cardiodesfibriladores. Así mismo, es indispensable tener en cuenta no sólo el riesgo de mortalidad de los pacientes sino también su funcionalidad y fragilidad para definir si se benefician o no de estos dispositivos.
Abstract The prevention of sudden death, to increase the survival, and quality of life in patients with heart failure, are the main indications for the use of implantable defibrillators and cardiac resynchronisation therapy, respectively. There is confidence in the clinical efficacy of these devices for the general population, but it is not so clear in patients over 70 years-old, given that this population is not sufficiently represented in clinical study designs. Although the evidence available up until now shows that there is a benefit in this age group for the use cardiac resynchronisation therapy, the use of cardiac defibrillators is questionable. It is also indispensable to not only to take into account the mortality risk in these patients, but also their functionality and frailty in order to determine whether or not they would benefit from these devices.